ECSP12011755A - BENZOXAZEPINE COMPOUNDS AS PI3K INHIBITORS AND METHODS OF USE - Google Patents

BENZOXAZEPINE COMPOUNDS AS PI3K INHIBITORS AND METHODS OF USE

Info

Publication number
ECSP12011755A
ECSP12011755A ECSP12011755A ECSP12011755A EC SP12011755 A ECSP12011755 A EC SP12011755A EC SP12011755 A ECSP12011755 A EC SP12011755A EC SP12011755 A ECSP12011755 A EC SP12011755A
Authority
EC
Ecuador
Prior art keywords
methods
compounds
benzoxazepine
pi3k inhibitors
benzoxazepine compounds
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Nicole Blaquiere
Steven Do
Danette Dudley
Adrian J Folkes
Robert Heald
Timothy Heffron
Mark Jones
Aleksandr Kolesnikov
Chudi Ndubaku
Alan G Olivero
Stephen Price
Steven Staben
Lan Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43037239&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12011755(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ECSP12011755A publication Critical patent/ECSP12011755A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La invención se refiere a compuestos de benzoxazepina de la fórmula Iincluidos los estereoisómeros, isómeros geométricos, tautómeros y las sales farmacéuticamente aceptables de los mismos, en la que: Z1 es CR1 o N; Z2 es CR2 o N; Z3 es CR3 o N; Z4 es CR4 o N; y B es un anillo pirazolilo, imidazolilo o triazolilo fusionado con el anillo de la benzoxazepina, dichos compuestos tienen actividad anticancerosa y, más específicamente, inhiben la actividad de la quinasa PI3.The invention relates to benzoxazepine compounds of the formula including stereoisomers, geometric isomers, tautomers and pharmaceutically acceptable salts thereof, wherein: Z1 is CR1 or N; Z2 is CR2 or N; Z3 is CR3 or N; Z4 is CR4 or N; and B is a pyrazolyl, imidazolyl or triazolyl ring fused with the benzoxazepine ring, said compounds have anticancer activity and, more specifically, inhibit the activity of the PI3 kinase.

ECSP12011755 2009-09-28 2012-03-28 BENZOXAZEPINE COMPOUNDS AS PI3K INHIBITORS AND METHODS OF USE ECSP12011755A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24638109P 2009-09-28 2009-09-28
US33068510P 2010-05-03 2010-05-03

Publications (1)

Publication Number Publication Date
ECSP12011755A true ECSP12011755A (en) 2012-05-30

Family

ID=43037239

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12011755 ECSP12011755A (en) 2009-09-28 2012-03-28 BENZOXAZEPINE COMPOUNDS AS PI3K INHIBITORS AND METHODS OF USE

Country Status (32)

Country Link
US (7) US8242104B2 (en)
EP (3) EP2483278B1 (en)
JP (2) JP5540101B2 (en)
KR (1) KR101428346B1 (en)
CN (2) CN104744491B (en)
AR (1) AR078187A1 (en)
AU (1) AU2010299816C1 (en)
BR (1) BR112012006807A2 (en)
CA (1) CA2772691C (en)
CL (1) CL2012000754A1 (en)
CO (1) CO6491026A2 (en)
CR (1) CR20120121A (en)
DK (1) DK2483278T3 (en)
EC (1) ECSP12011755A (en)
ES (2) ES2444779T3 (en)
HK (2) HK1174629A1 (en)
HR (1) HRP20140229T1 (en)
IL (2) IL217558A (en)
MA (1) MA33531B1 (en)
MX (1) MX2012003591A (en)
MY (2) MY160064A (en)
NZ (1) NZ597833A (en)
PE (1) PE20121025A1 (en)
PL (1) PL2483278T3 (en)
PT (1) PT2483278E (en)
RS (1) RS53164B (en)
RU (2) RU2600927C2 (en)
SG (1) SG10201405049RA (en)
SI (1) SI2483278T1 (en)
TW (1) TWI423980B (en)
WO (1) WO2011036280A1 (en)
ZA (1) ZA201202199B (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2464645T1 (en) * 2009-07-27 2017-10-30 Gilead Sciences, Inc. Fused heterocyclic compounds as ion channel modulators
EP2483278B1 (en) * 2009-09-28 2013-12-25 F. Hoffmann-La Roche AG Benzoxazepin pi3k inhibitor compounds and their use in the treatment of cancer
PE20121559A1 (en) * 2009-09-28 2012-12-05 Hoffmann La Roche BENZOXEPINE COMPOUNDS, P13K INHIBITORS
CN103096977B (en) 2010-07-02 2017-02-15 吉利德科学公司 Fused heterocyclic compounds as ion channel modulators
BR112013024122A2 (en) * 2011-03-21 2019-09-24 Hoffmann La Roche p110 delta pi3k selective benzoxazepine compounds and methods of use
CN103649056B (en) 2011-05-10 2016-04-27 吉利德科学公司 As the condensed heterocyclic compouds of ion channel modulators
WO2012156379A1 (en) 2011-05-13 2012-11-22 Universität Zürich PIK3/P110α INHIBITORS FOR PREVENTION OF RESTENOSIS BY APPLICATION AS AN IMPLANT COATING
NO3175985T3 (en) * 2011-07-01 2018-04-28
TW201837023A (en) 2011-07-01 2018-10-16 美商基利科學股份有限公司 Fused heterocyclic compounds as ion channel modulators
KR20140131359A (en) * 2012-02-17 2014-11-12 에프. 호프만-라 로슈 아게 Tricyclic compounds and methods of use therefor
KR101689946B1 (en) * 2012-06-08 2016-12-26 에프. 호프만-라 로슈 아게 Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer
EP2872161B1 (en) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol for use in treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or ahi1 dysregulations or mutations
CN102775395A (en) * 2012-07-12 2012-11-14 江苏七洲绿色化工股份有限公司 Preparation method of propiconazole and propiconazole intermediate
US9303046B2 (en) * 2012-08-07 2016-04-05 Janssen Pharmaceutica Nv Process for the preparation of heterocyclic ester derivatives
EP3845540A1 (en) * 2013-03-13 2021-07-07 F. Hoffmann-La Roche AG Intermediates for the synthesis of benzoxazepin compounds
JP2016519684A (en) 2013-04-08 2016-07-07 デニス エム ブラウン Methods and compositions for improving the efficacy of suboptimally administered medication and / or reducing side effects
US9266903B2 (en) * 2013-12-16 2016-02-23 Genentech, Inc. Polymorphs of 2-(4-(2-(1-isopropyl-3-methyl-1H-1,2,4-triazole-5-yl)-5,6-dihydrobenzo[F]imidazo [1,2-D][1,4]oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide, methods of production, and pharmaceutical uses thereof
RU2016137122A (en) 2014-03-13 2018-04-18 Ф. Хоффманн-Ля Рош Аг THERAPEUTIC COMBINATIONS WITH MODULATORS OF ESTROGEN RECEPTORS
US10239845B2 (en) 2015-02-02 2019-03-26 Forma Therapeutics, Inc. 3-aryl-4-amido-bicyclic [4,5,0] hydroxamic acids as HDAC inhibitors
WO2016126726A1 (en) 2015-02-02 2016-08-11 Forma Therapeutics, Inc. Bicyclic [4,6,0] hydroxamic acids as hdac6 inhibitors
AR104068A1 (en) 2015-03-26 2017-06-21 Hoffmann La Roche COMBINATIONS OF A 3-KINASE PHOSFOINOSYTIDE INHIBITOR COMPOSITE AND A CDK4 / 6 INHIBITOR COMPOUND FOR CANCER TREATMENT
US10351576B2 (en) * 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
EP3314265B1 (en) 2015-06-29 2019-07-24 H. Hoffnabb-La Roche Ag Methods of treatment with taselisib
SI3317284T1 (en) * 2015-07-02 2020-02-28 F. Hoffmann-La Roche Ag Benzoxazepin oxazolidinone compounds and methods of use
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
CN108349996B (en) * 2015-09-08 2021-01-08 豪夫迈·罗氏有限公司 Tricyclic PI3K inhibitor compounds and methods of use thereof
US9721369B2 (en) * 2015-09-15 2017-08-01 Facebook, Inc. Systems and methods for utilizing multiple map portions from multiple map data sources
US10555935B2 (en) 2016-06-17 2020-02-11 Forma Therapeutics, Inc. 2-spiro-5- and 6-hydroxamic acid indanes as HDAC inhibitors
TW201815787A (en) 2016-09-23 2018-05-01 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201825465A (en) 2016-09-23 2018-07-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
TW201813963A (en) 2016-09-23 2018-04-16 美商基利科學股份有限公司 Phosphatidylinositol 3-kinase inhibitors
AU2017333782A1 (en) 2016-09-29 2019-03-28 Bayer Aktiengesellschaft Novel 5-substituted imidazolylmethyl derivatives
EP3555107B1 (en) * 2016-12-15 2021-02-17 H. Hoffnabb-La Roche Ag Process for the preparation of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide
AU2018227788B2 (en) 2017-03-02 2021-04-22 F. Hoffmann-La Roche Ag Adjuvant treatment of HER2-positive breast cancer
AU2018259089B2 (en) * 2017-04-28 2022-05-12 F. Hoffmann-La Roche Ag Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo(ƒ)imidazo(1,2-d)(1,4)oxazepin-9-yl)amino)propanamide, and methods of production
JP7230041B2 (en) * 2017-10-26 2023-02-28 ザイノミック・ファーマシューティカルズ・インコーポレイテッド Crystalline salt of B-RAF kinase inhibitor
EP3805231A4 (en) * 2018-05-30 2022-01-12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
CN111909157B (en) * 2019-05-07 2023-02-03 南京药石科技股份有限公司 EZH2 inhibitors and uses thereof
US20230053342A1 (en) * 2019-11-04 2023-02-23 Betta Pharmaceuticals Co., Ltd Imidazolidinone compound, preparation method therefor and use thereof
CN114599656A (en) * 2019-11-04 2022-06-07 贝达药业股份有限公司 Imidazolidinone compound and preparation method and application thereof
JP2023503010A (en) * 2019-11-25 2023-01-26 上▲海▼翰森生物医▲薬▼科技有限公司 Salts or Crystalline Forms Containing Three Fused Ring Derivatives and Pharmaceutical Compositions Thereof
AU2022275275A1 (en) 2021-05-13 2023-12-14 Betta Pharmaceuticals Co., Ltd Polymorph of imidazolidinone compound, preparation method therefor and use thereof
AR125993A1 (en) 2021-05-28 2023-08-30 Genentech Inc PROCESS FOR THE PREPARATION OF BENZOXAZEPINE OXAZOLIDINONE COMPOUNDS

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB8504702D0 (en) * 1985-02-23 1985-03-27 Zyma Sa Tricyclic compounds
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
FR2677356B1 (en) * 1991-06-05 1995-03-17 Sanofi Sa HETEROCYCLIC DERIVATIVES OF SUBSTITUTED ACYLAMINO-2 THIAZOLES-5, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME.
WO1994014777A1 (en) * 1992-12-28 1994-07-07 Eisai Co., Ltd. Heterocyclic carbonic acid derivatives which bind to retinoid receptors (rar)
AU678503B2 (en) * 1993-09-24 1997-05-29 Takeda Chemical Industries Ltd. Condensed heterocyclic compounds and their use as squalene synthetase inhibitors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
JPH08336393A (en) 1995-04-13 1996-12-24 Mitsubishi Chem Corp Production of optically active gamma-substituted-beta-hydroxybutyric ester
AU1272597A (en) * 1995-11-17 1997-06-11 E.I. Du Pont De Nemours And Company Tricyclic herbicidal heterocycles
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
DE19908533A1 (en) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclic thiazole systems, processes for their preparation and medicaments containing these compounds
DE19908535A1 (en) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Use of polycyclic thiazole systems for the preparation of medicaments for the prophylaxis or treatment of obesity
DE19908537A1 (en) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Use of polycyclic 2-amino-thiazole systems for the preparation of medicaments for the prophylaxis or treatment of obesity
DE19908538A1 (en) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclic 2-amino-thiazole systems, processes for their preparation and medicaments containing these compounds
US7273880B2 (en) * 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
AU2001246494A1 (en) 2000-03-03 2001-09-12 Novartis Ag Condensed thiazolamines and their use as neuropeptide y5 antagonists
CZ20032098A3 (en) 2001-02-02 2004-01-14 Schering Corporation 3,4-Disubstituted cyclobutene-1,2-diones and pharmaceutical composition containing thereof
TWI232863B (en) * 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
CA2492922A1 (en) * 2002-07-19 2004-01-29 Pharmacia Corporation Substituted thiophene carboxamide compounds for the treatment of inflammation
CA2514241A1 (en) * 2003-02-07 2004-08-19 Warner-Lambert Company Llc Oxazolidinone derivates n-substituted by a tricyclic ring, for use as antibacterial agents
TW200510356A (en) * 2003-08-01 2005-03-16 Takeda Chemical Industries Ltd Benzoxaepine compounds
US20050239767A1 (en) * 2003-10-28 2005-10-27 Chan Michael K Intermolecular SNAr of the heterocycle-activated nitro and fluoro groups-application in the synthesis of polyazamacrocyclic ligands
KR20070039885A (en) * 2004-07-01 2007-04-13 머크 앤드 캄파니 인코포레이티드 Mitotic kinesin inhibitors
MX2007004051A (en) * 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3 kinases.
EA032466B1 (en) 2005-10-07 2019-05-31 Экселиксис, Инк. Methods of making mek inhibitors
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole
GB0610866D0 (en) * 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
CA2659280A1 (en) * 2006-07-28 2008-01-31 Alcan Packaging Flexible France Coextruded film with polylactic acid (pla) and ethylene vinyl acetate (eva)
EP2054058B1 (en) 2006-08-04 2016-11-09 Beth Israel Deaconess Medical Center Inhibitors of pyruvate kinase and methods of treating disease
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
DK2439205T3 (en) * 2006-12-29 2015-06-22 Abbvie Deutschland Carboxamide compounds and their use as calpain inhibitors
CN101868254B (en) 2007-09-19 2013-08-21 加利福尼亚大学董事会 Positron emission tomography probes for imaging immune activation and selected cancers
PE20091720A1 (en) * 2008-03-31 2009-11-26 Genentech Inc BENZOPYRANE AND BENZOXEPINE COMPOUNDS AS PI3K INHIBITORS
EP2350084B1 (en) * 2008-10-17 2015-06-24 Boehringer Ingelheim International GmbH Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (pi3-kinases) inhibitor
EP2483278B1 (en) * 2009-09-28 2013-12-25 F. Hoffmann-La Roche AG Benzoxazepin pi3k inhibitor compounds and their use in the treatment of cancer
PE20121559A1 (en) * 2009-09-28 2012-12-05 Hoffmann La Roche BENZOXEPINE COMPOUNDS, P13K INHIBITORS

Also Published As

Publication number Publication date
JP2014070075A (en) 2014-04-21
MX2012003591A (en) 2012-04-19
ES2444779T3 (en) 2014-02-26
CN102762576B (en) 2015-04-22
EP2845592A1 (en) 2015-03-11
SI2483278T1 (en) 2014-03-31
CA2772691A1 (en) 2011-03-31
IL217558A0 (en) 2012-02-29
US20110076292A1 (en) 2011-03-31
US20140058098A1 (en) 2014-02-27
IL217558A (en) 2015-06-30
CN104744491B (en) 2017-07-11
ES2570569T3 (en) 2016-05-19
RU2654068C1 (en) 2018-05-16
CN104744491A (en) 2015-07-01
US20120244149A1 (en) 2012-09-27
ZA201202199B (en) 2013-01-30
MY160064A (en) 2017-02-15
CN102762576A (en) 2012-10-31
TWI423980B (en) 2014-01-21
NZ597833A (en) 2014-01-31
CL2012000754A1 (en) 2012-09-07
CA2772691C (en) 2017-10-03
CR20120121A (en) 2012-06-01
HK1174629A1 (en) 2013-06-14
US8785626B2 (en) 2014-07-22
AR078187A1 (en) 2011-10-19
PE20121025A1 (en) 2012-08-06
MY184074A (en) 2021-03-17
RU2012117398A (en) 2013-11-10
AU2010299816C1 (en) 2018-02-01
US9198918B2 (en) 2015-12-01
JP2013505917A (en) 2013-02-21
WO2011036280A1 (en) 2011-03-31
HK1211929A1 (en) 2016-06-03
BR112012006807A2 (en) 2020-11-03
CO6491026A2 (en) 2012-07-31
IL239081A0 (en) 2015-07-30
EP2711368A1 (en) 2014-03-26
US9546178B2 (en) 2017-01-17
KR20120065431A (en) 2012-06-20
US8242104B2 (en) 2012-08-14
PL2483278T3 (en) 2014-05-30
EP2711368B1 (en) 2016-03-23
US8343955B2 (en) 2013-01-01
US20170081341A1 (en) 2017-03-23
DK2483278T3 (en) 2014-01-13
IL239081B (en) 2018-05-31
HRP20140229T1 (en) 2014-04-11
JP5625101B2 (en) 2014-11-12
SG10201405049RA (en) 2014-10-30
JP5540101B2 (en) 2014-07-02
US20130079331A1 (en) 2013-03-28
US20160052933A1 (en) 2016-02-25
RS53164B (en) 2014-06-30
AU2010299816A1 (en) 2012-02-02
US8586574B2 (en) 2013-11-19
EP2483278B1 (en) 2013-12-25
EP2483278A1 (en) 2012-08-08
TW201127844A (en) 2011-08-16
US20140288047A1 (en) 2014-09-25
MA33531B1 (en) 2012-08-01
RU2600927C2 (en) 2016-10-27
KR101428346B1 (en) 2014-08-07
US9670228B2 (en) 2017-06-06
PT2483278E (en) 2014-03-05
AU2010299816B2 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
ECSP12011755A (en) BENZOXAZEPINE COMPOUNDS AS PI3K INHIBITORS AND METHODS OF USE
CR20120643A (en) DERIVATIVES OF IMIDAZOPIRIDINE, ITS PREPARATION PROCEDURE AND ITS APPLICATION IN THERAPY
CR20120130A (en) BENZOXEPINE COMPOUNDS INHIBITORS OF THE PI3K AND METHODS OF USE
UA111640C2 (en) DERIVATIVES [1,2,3] TRIAZOLO [4,5-d] PYRIMIDINE AS A cannabinoid receptor agonist 2
CR20120469A (en) COMPOSITE OF PIRAZOL-4-IL-HETEROCICLIL-CARBOXAMIDE AND METHODS OF USE
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MY196427A (en) Piperidinyl Indole Derivatives And Their Use As Complement Factor B Inhibitors
CR20140032A (en) TETRAHYDROPIRIDO-PIRIDINA AND TETRAHIDROPIRIDO-PIRIMIDINA COMPOUNDS AND THEIR USE AS MODULAR RECEPTORS OF C5A
CO6361936A2 (en) IMIDAZOPIRIDAZINACARBONITRILOS USEFUL AS QUINASE INHIBITORS
GT201400196A (en) HETEROCICLYL COMPOUNDS
UY35834A (en) PIPERAZINAS DE PIRAZOLO REPLACED AS INHIBITORS OF CASEÍNA QUINASA 1 DELTA AND EPSILON
CR20120427A (en) PIRAZOL DERIVATIVES AS JAK INHIBITORS
DOP2012000321A (en) INDOLIZINE DERIVATIVES, THEIR PREPARATION PROCEDURE AND THEIR APPLICATION IN THERAPEUTICS
CO6640327A2 (en) Pyrazole compounds as sigma receptor inhibitors
DOP2011000260A (en) FUSIONATED PYRIMIDINS
NI200900183A (en) PYRID [2,3-D] PYRIMIDINE - 7 - ONA COMPOUNDS AS PI3K - ALPHA INHIBITORS FOR THE TREATMENT OF CANCER.
CU20130139A7 (en) GLOCOSID DERIVATIVES AND USES OF THE SAME
NI201300125A (en) DERIVATIVES OF 2 - AMINO - 3 - (IMIDAZOL - 2 - IL) - PYRIDIN - 4 - ONA AND THEIR USE AS KINASE INHIBITORS OF THE VEGF RECEPTOR.
AR092772A1 (en) DERIVATIVE OF 7-AZAINDOL
MX2016006667A (en) Pyrrolopyrrolone derivatives and their use as bet inhibitors.
MX345336B (en) Benzoxazepin pi3k inhibitor compounds and methods of use.
CY1115090T1 (en) Benzoxazepine compounds as RISK inhibitors and their use for cancer treatment
UA107808C2 (en) Benzoxazepin inhibitors ri3k and their applications
CU20100125A7 (en) BIS- (SULFONYLAMINE) DERIVATIVES FOR USE IN THERAPY
UY35672A (en) DERIVATIVES OF AMINO-METHYL-BIARYL AS INHIBITORS OF THE COMPLEMENT FACTOR D AND USES OF THE SAME